OncoMatch/Clinical Trials/NCT05859750
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Is NCT05859750 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for pancreatic cancer.
Treatment: AK104 · AK104 · Gemcitabine · Nab-Paclitaxel · Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate · Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin — This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line therapy in subjects with advanced unresectable or metastatic pancreatic ductal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 germline mutation
Excluded: BRCA2 germline mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: treatment targeting the mechanism of tumor immunity
Patients who received any prior treatments targeting the mechanism of tumor immunity [excluded].
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05859750 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with BRCA1 alterations eligible?
No. BRCA1 germline mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 germline mutation is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages